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Abstract Wortmannin has been shown to be a non-competitive
and irreversible inhibitor of PI3 kinase. For this reason, it has
attracted considerable interest and it has been used, as a selective
inhibitor of the PI3 kinase, for the study of signal transduction
pathways in different systems including Xenopus oocytes. We
show here that wortmannin itself is able to induce meiotic
maturation at doses slightly higher that those required for
complete inhibition of PI3 kinase. This effect was shown to be
independent of the ability to inhibit PI3K since another unrelated
PI3K inhibitor, LY294002, was unable to induce oocyte
maturation at inhibitory concentrations for PI3 kinase. The
mechanism for wortmannin-induced maturation involves the
activation of maturation promoting factor (MPF) and MAP
kinase activities in a time course that preceded the appearance of
germinal vesicle breakdown. Thus, the pathway activated by
wortmannin directly or indirectly affects other protein or
proteins, besides PI3 kinase, responsible for its activity. This
new target is placed independently or downstream of the PI3
kinase inhibition and upstream of protein synthesis. Moreover,
the inhibition of either MPF or cAMP phosphodiesterase blocks
wortmannin-induced maturation. We conclude that wortmannin
may be a valuable tool for the study of the pathway leading to
mitotic maturation of oocytes, but cannot be used as a specific
PI3 kinase inhibitor.
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1. Introduction
The induction of oocyte maturation by agonists is known to
involve an initial action of activation of their receptors. After
progesterone or insulin treatment activation of maturation
promoting factor (MPF) from an inactive state takes place
prior to germinal vesicle breakdown (GVBD). This activation
is necessary and su⁄cient to induce GVBD (for review see [1^
4]). The injection of active MPF induces precocious GVBD [5]
and the microinjection of p13suc protein, which speci¢cally
binds to the cdc2 protein (the kinase component of the
MPF complex), inhibits its kinase activity blocking the matu-
ration process [6]. In the case of progesterone, there are two
peaks of MPF activity, the ¢rst one coincides approximately
with metaphase I and needs synthesis of c-Mos protein for
induction of activity [7]. The second peak appears in meta-
phase II and needs the resynthesis of cyclin B (the second
component of the MPF complex), which is destroyed at the
end of the ¢rst mitosis [3,8,9]. Thus, MPF is a complex of
cyclin B and cdc2, activation of which leads to a burst of
protein phosphorylation 30^60 min prior to GVBD. This plei-
otropic e¡ect leads to activation of molecules which are essen-
tial steps in the signal transduction pathways of oocyte matu-
ration.
The c-Mos proto-oncogene acts as a meiotic initiator pro-
tein. Microinjection of Mos protein or mRNA induces MPF
activity, GVBD and progression through meiosis I and II
[7,10]. On the other hand, antisense ablation of c-mos
mRNA blocks oocyte maturation and MPF activity induced
by progesterone [7]. The protein synthesis requirement for
MPF activation can be ascribed mainly to Mos translation,
though recently it has been shown that the de novo synthesis
of a cdc2 binding protein also plays an important role [11].
Increased synthesis of Mos kinase leads to mitogen-associ-
ated protein (MAP) kinase activation via activation of MEK.
MEK is a direct target of Mos, and thus Mos acts as a
MAPK kinase kinase [12,13]. Activation of the MAP kinase
cascade by injection of a constitutively active MEK mutant
may be su⁄cient for induction of MPF and GVBD [14^16].
Furthermore, using the MAPK phosphatase, CL100, or anti-
bodies that neutralize MAPK activity, it has been shown that
MAPK activation is essential for progesterone- and Mos-in-
duced maturation and MPF activation [15]. Finally, injection
of puri¢ed MPF into immature oocytes or the addition to
interphase egg extracts activates endogenous MEK and
MAPK [5,17]. Based on these and other indications, it has
been proposed that Mos, MAPK and MPF all fall in a feed-
back loop that promotes maturation of Xenopus oocytes (for
review see [18,19]).
Wortmannin, a fungal metabolite, has attracted consider-
able interest since it has been reported to directly inhibit PI3
kinase [20^22]. In fact, it has been used as a selective inhibitor
for the study of signal transduction pathways in di¡erent sys-
tems [23^28]. Wortmannin has been shown to be a non-com-
petitive and irreversible inhibitor of PI3 kinase at nanomolar
concentrations with no e¡ect on PI4 kinase, protein kinase C
or protein tyrosine kinases, although it has been also reported
to be an inhibitor of myosin light chain kinase at micromolar
concentrations [21]. However, the speci¢city of wortmannin
has recently been subject to controversy [29,30].
In order to test whether wortmannin is a speci¢c inhibitor
of PI3 kinase or can have other non-speci¢c biological e¡ects
through other proteins we tested the e¡ect of this drug in the
Xenopus laevis oocyte system. We show that wortmannin itself
induces meiotic maturation at slightly higher doses that those
required for complete inhibition of PI3 kinase. This activity
was associated with MPF and p42MAPK activation. The char-
acterization of the pathway that leads to maturation by wort-
mannin treatment is presented.
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2. Materials and methods
2.1. Oocyte maturation
Stage VI oocytes were selected by manual dissection. Series of 30^
50 oocytes were treated for hormonal induction of maturation with
1 Wg/ml progesterone or the indicated concentrations of wortmannin
in Ringer’s bu¡er (100 mM NaCl, 1.8 mM KCl, 2 mM MgCl2, 1 mM
CaCl2, 4 mM NaHCO3 pH 7.8). After 18^20 h of incubation at 18^
20‡C in Ringer’s bu¡er, oocytes were lysed for biochemical character-
ization or ¢xed in 16% TCA. Visual veri¢cation of nuclear vesicle
breakdown was performed by open splitting the oocytes after ¢xation.
2.2. MPF assays
MPF assays were carried out with total extracts from series of 10
oocytes treated with progesterone or wortmannin. After incubation
for 18^20 h oocytes were homogenized in bu¡er BLO (20 mM HEPES
pH 7.0, 10 mM L-glycerophosphate, 5 mM EGTA, 5 mM MgCl2, 50
mM NaF, 2 mM DTT, 10 Wg/ml leupeptin, 25 Wg/ml aprotinin and
100 WM PMSF). Following centrifugation at 13 000Ug for 15 min,
extracts were assayed for 15 min at 30‡C in a ¢nal reaction volume of
50 Wl containing 20 mM HEPES pH 7.0, 5 mM L-mercaptoethanol, 10
mM MgCl2, 100 WM [32P]QATP (2^5 dpm/fmol), 0.2 Wg of PKA in-
hibitor and 1 mg/ml of type III-S calf thymus histone (Sigma). Re-
actions were stopped by addition of PAGE sample bu¡er and boiling
for 5 min. Samples were run in a 15% PAGE, dried and exposed at
370‡C.
2.3. Inmunoblots
Extracts from Xenopus oocytes in BLO supplied to 1 mM PMSF
were resolved in SDS-10% polyacrylamide gels. Gels were transferred
electrophoretically to 0.45 Wm nitrocellulose paper (Biotech, SL) and
incubated with antibodies speci¢c for MAP kinase. After incubation
with the corresponding antibody, the inmunoblots were developed by
the ECL system according to the manufacturer (Amersham).
For detection of MAP kinase, an antibody against the peptide
KERLKELIFQETAR from the carboxy-terminal region of human
MAP-1 kinase was used.
3. Results
3.1. Wortmannin induces maturation of Xenopus laevis oocytes
To study the possible in£uence of wortmannin on Xenopus
oocytes we tested di¡erent concentrations of the drug from
nanomolar to micromolar, and found that wortmannin totally
inhibited PI3 kinase in inmunoprecipitates at a concentration
of 10^100 nM (data not shown), in agreement with previous
publications from other groups [20,28,31]. In fact, Liu and co-
workers have recently shown that at 100 nM wortmannin
Xenopus oocyte PI3 kinase is completely blocked in vivo
[28]. We next investigated the e¡ect of the drug on GVBD.
Fig. 1A shows that concentrations of wortmannin lower than
50 nM did not induce GVBD. At concentrations of 100 nM, a
partial biological activity was observed with a 20^40% induc-
tion of GVBD after 20 h of incubation. At concentrations
higher than 100 nM, wortmannin treatment induced meiotic
maturation in oocytes exposed to the drug. In several experi-
ments 200 nM of wortmannin was able to induce a signi¢cant
percentage of maturation (70^100%) depending of the batch
of oocytes, with a mean value of 85 þ 15% (n = 5), while 1 WM
always induces 100% maturation.
In order to study the in£uence of wortmannin on the time
of events leading to GVBD, several concentrations were used
(Fig. 1B). All control oocytes as well as those treated with 10
or 50 nM wortmannin showed either no or very little e¡ect on
the germinal vesicle after 20 h of incubation. By contrast, 30%
of the oocyte population underwent GVBD at 100 nM. In
oocytes treated at 200 nM, we found GVBD after 10^12 h
of treatment.
The above results may be explained if inhibition of PI3
kinase was su⁄cient to trigger GVBD. Therefore, wortmannin
would be inducing GVBD by its ability to inhibit PI3 kinase.
We then investigated whether inhibition of PI3 kinase by an
alternative, unrelated compound such as LY294002, was also
able to induce GVBD at concentrations that drastically inhibit
PI3 kinase. As shown in Fig. 1C, LY294002 was unable to
induce GVBD at concentrations of up to 20 WM, previously
shown to completely inhibit PI3 kinase in Xenopus laevis oo-
cytes [32]. Thus the e¡ects observed after treatment of the
oocytes with wortmannin were not a consequence of inhibi-
tion of PI3 kinase.
3.2. MPF activation can be detected after wortmannin
treatment
To assess the functional importance of wortmannin-induced
GVBD we analyzed the activation of the MPF complex,
which can serve as a biochemical marker of maturation. We
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Fig. 1. Induction of GVBD by wortmannin. A: Dose response of
wortmannin-induced GVBD. Oocytes were incubated in Ringer’s
bu¡er with di¡erent concentrations of wortmannin. GVBD was ana-
lyzed 18 h after treatment as described in Section 2 by ¢xing in
10% TCA. B: Time course of wortmannin-induced GVBD. Oocytes
were incubated in 10 (a), 50 (b), 100 (O) or 200 (F) nM wortman-
nin. GVBD was analyzed at di¡erent times after ¢xation in 10%
TCA as indicated in A. C: E¡ect of PI3 kinase inhibition on
GVBD. Batches of 40 oocytes were treated with the indicated con-
centrations of either wortmannin (100 nM or 1000 nM) or
LY294002 (2, 5, 10 or 20 WM) and GVBD scored at 20 h as indi-
cated in A.
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determined ¢rst the activation of MPF after 20 h of exposure
to di¡erent concentrations of wortmannin. As shown in Fig.
2A, treatment with 10 or 50 nM does not induce MPF acti-
vation, correlating with the lack of GVBD induction. At 100
nM, wortmannin induced partial activation of MPF (Fig. 2)
and partial induction of GVBD, with about 20^40% of ma-
ture oocytes (Fig. 1). Incubation with over 100 nM wortman-
nin induced MPF activation at a comparable level to that
observed after progesterone treatment (Fig. 2).
We next characterized the sequence of events leading to
GVBD induced by wortmannin. We analyzed the time course
of activation of H1 kinase activity. Oocytes were exposed to
wortmannin and at indicated times, samples were frozen at
370‡C. Oocytes were processed and H1 kinase activity as-
sayed as described in Section 2. As shown in Fig. 2B, 100
nM of wortmannin induced a partial MPF activity (170^
190%) only at late times, in agreement with the partial
GVBD (30%) observed after 16^20 h of exposure to the
drug. In 200 nM wortmannin-treated oocytes, MPF was in-
duced with a kinetics slightly preceding GVBD. Partial MPF
activity was observed after 8 h of exposure (160%) when only
15% GVBD was observed. At 10 h of treatment, 60% GVBD
was observed along with 240% MPF activity, near to maximal
MPF activity observed after 16 h of exposure. Thus, MPF
activation preceded and correlated with the observed GVBD.
3.3. Activation of MAP kinase follows wortmannin treatment
In Xenopus oocytes p42MAPK can be activated as a con-
sequence of MPF activation (see Section 1). Moreover, acti-
vation of the MAP kinase pathway seems to be necessary for
progesterone-induced maturation [14,33]. Thus, we analyzed
the phosphorylated state of MAP kinase. As previously dem-
onstrated, phosphorylation of this protein leads to its activa-
tion and this process can be followed by its mobility shift on
bisacrylamide-polyacrylamide gel electrophoresis [34]. As
shown in Fig. 3A, treatment with doses lower than 100 nM
wortmannin, which did not induce GVBD, did not alter
MAPK mobility. However, a dose of 1 WM wortmannin,
which induced oocyte entry into GVBD, also induced a shift
in the mobility of MAPK, indicating that most of the protein
is phosphorylated and activated. Finally, in keeping with this
observation, treatment with 100 nM wortmannin was able to
induce a partial MPF activity and a partial activation of MAP
kinase, most likely a consequence of the small percentage of
oocytes that underwent GVBD (Fig. 3A).
We also analyzed the time course for MAP kinase activa-
tion after wortmannin treatment. Oocytes were exposed to
wortmannin and every 2 h kept frozen at 370‡C. Oocytes
were processed and p42MAPK activation estimated by its
mobility shift on PAGE. As shown in Fig. 3B, 100 nM of
wortmannin induced a partial MAPK activation only at late
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Fig. 3. MAP kinase activation by wortmannin treatment. Activation
of the p42MAPK was measured by Western blot as its mobility shift
after electrophoresis in polyacrylamide gels. Total extracts of un-
stimulated or wortmannin-stimulated oocytes were run in a 10%
PAGE, transferred to nitrocellulose and incubated in the presence
of an K-MAP kinase (polyclonal) antibody, followed by a biotiny-
lated anti-rabbit antibody and the streptavidin-peroxidase-conju-
gated protein. Blots were developed with the ECL system as recom-
mended by the manufacturer (Amersham). A: MPF activation at
di¡erent concentrations of wortmannin. Oocytes were treated with
di¡erent concentrations of wortmannin and after 18 h were proc-
essed as described in Section 2. B: Time course of MPF activation
induced by wortmannin. Oocytes were treated with 100 or 200 nM
wortmannin. At indicated times, oocytes were placed on ice and
processed for the mobility shift assay as described in Section 2.
Fig. 2. MPF activation by wortmannin treatment. A: MPF activa-
tion at di¡erent concentrations of wortmannin. Oocytes were treated
with indicated concentrations of wortmannin and after 18 h proc-
essed for MPF activity as described in Section 2. B: Time course of
MPF activation induced by wortmannin. Oocytes were treated with
100 nM (R) or 200 nM (b) wortmannin. At indicated times, oo-
cytes were placed on ice and processed for the MPF assay as de-
scribed in Section 2. The phosphorylated band corresponding to the
H1 protein was cut and counted.
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times, in agreement with the observed partial GVBD induc-
tion and the partial MPF activation after 16^20 h of exposure
to the drug. In 200 nM wortmannin-treated oocytes, MAP
kinase was activated with a kinetics slightly preceding the
appearance of GVBD. A partial MAP kinase activation was
observed after 8 h of exposure to the drug, and activation of
MAP kinase correlated with the MPF activity and GVBD
observed. Thus, MAP kinase activation preceded GVBD,
and parallelled with MPF activity.
3.4. Inhibition of wortmannin-induced meiotic maturation by
6-DMAP, IBMX and cycloheximide (CHX)
6-Dimethyl-aminopurine (6-DMAP) is a serine/threonine
kinase inhibitor that induces MPF inactivation when applied
to Xenopus oocytes [33,35]. We tested whether the activation
of MPF is necessary for wortmannin-induced GVBD. Oocytes
were treated with di¡erent concentrations of wortmannin and
incubated in the presence of 0.5 mM 6-DMAP. After 20 h
incubation, none of the oocytes showed GVBD (Fig. 4). Thus,
6-DMAP blocks the meiotic maturation induced by wortman-
nin, as previously reported for progesterone treatment [33,35].
In Xenopus oocytes, initiation of maturation has been re-
ported to rely on the reduction of cAMP-dependent protein
kinase activity [36] and the synthesis of the c-Mos protein [10].
We tested whether maturation induced by wortmannin is able
to bypass these requirements. Oocytes were treated with 1 mM
IBMX, which inhibits the cAMP phosphodiesterase activity
induced by maturation inducers [36,37], or 20 WM CHX,
which inhibits protein synthesis more than 90% [38]. Oocytes
were incubated in the presence of the inhibitors and then
treated with di¡erent concentrations of wortmannin. High
concentrations of wortmannin did not induce GVBD in the
presence of either inhibitor (Fig. 4).
To assess further whether GVBD induced by wortmannin
depends upon the pathway blocked by these inhibitors we
analyzed MPF activation, as a biochemical marker, in the
presence of the inhibitors. As shown in Fig. 4, CHX, IBMX
and 6-DMAP inhibited MPF activation induced by wortman-
nin, indicating that activation of the maturation pathway by
wortmannin precedes protein synthesis. Furthermore, these
results also provide evidence that both cAMP phosphodiester-
ase and MPF activation are required.
4. Discussion
Wortmannin has been reported to be a potent inhibitor of
PI3 kinase activity with ID50 values in the range of 10^100
nM. In Xenopus laevis oocytes wortmannin inhibits the PI3
kinase activity in vitro at concentrations as low as 10 nM
under experimental conditions of 0.1^1 nM concentrations
of ATP (results not shown) and at 100 nM Xenopus PI3 kin-
ase is fully inhibited in vivo [28]. We report here that wort-
mannin itself is able to induce meiotic maturation in oocytes,
an e¡ect that is not mediated by its ability to inhibit PI3
kinase, since another inhibitor of this enzyme, LY294002,
was not able to induce a similar e¡ect. The concentrations
needed for oocyte maturation were similar to those previously
reported for inhibition of serine/threonine kinases by wort-
mannin such as myosin light chain kinase (IC50 = 200 nM).
Moreover, it has been reported that other known inhibitors
of signalling molecules such as okadaic acid or propanol can
also induce oocyte maturation [39], making more complex the
proper evaluation of these results. Thus, our study suggests
that wortmannin has other cellular targets besides PI3 kinase
that may be important for signal transduction in eukaryotes.
We have also characterized the pathway induced by wort-
mannin that leads to GVBD. Wortmannin induced MPF ac-
tivation with a time course that precedes the appearance of
GVBD, indicating that activation of the complex cdc2-cyclin
B can be a requirement for wortmannin-induced GVBD.
Moreover, wortmannin induced MAP kinase activation.
These two processes showed a parallel kinetics after oocyte
stimulation by wortmannin, suggesting that both events may
be functionally linked.
We have further analyzed the pathway that leads to MPF
and MAPK activation by using di¡erent inhibitors which
have been previously characterized for their e¡ects on the
progesterone-induced pathway. 6-DMAP is a purine analogue
that inhibits oocyte maturation in several species, including
Xenopus oocytes [35,40,41], acting directly at the MPF activa-
tion level at the concentrations used in this study. Treatment
with 6-DMAP was able to inhibit in vitro and in vivo the
MPF activity [33], and completely inhibited maturation of
Xenopus oocytes induced by microinjection of active MPF
[35]. We found that 6-DMAP blocks both MPF activation
as well as GVBD induced by wortmannin.
Induction of Xenopus oocyte maturation by hormones de-
pends on protein synthesis [2]. Microinjection of active MPF
can bypass this requirement, suggesting that protein synthesis
is needed for activation of MPF. We analyzed the requirement
of protein synthesis for the GVBD induced by wortmannin.
The e¡ect was blocked in the presence of CHX, indicating
that wortmannin requires protein synthesis, and it activates
the GVBD pathway at a level upstream of the protein syn-
thesis step.
Inhibition of PKA is a requirement for both hormone and
oncogenic ras-p21 induced GVBD [36]. It has been found
recently that PKA acts at multiple points to inhibit Xenopus
oocyte maturation by preventing both Mos translation and
MPF activation [42]. It has been shown that progesterone,
insulin and oncogenic ras induce the activation of cAMP
phosphodiesterase [36,37] reducing the endogenous pool of
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Fig. 4. E¡ect of CHX, IBMX and 6-DMAP on wortmannin-in-
duced GVBD and MPF activity. Oocytes were prepared as de-
scribed in Section 2. Batches of 20^30 oocytes were treated with 200
nM of wortmannin (+) or bu¡er alone (3) in the presence or ab-
sence of 10 WM progesterone, 20 WM CHX, 10 mM IBMX or 0.5
mM 6-DMAP. Induction of GVBD was analyzed 18 h after treat-
ment by ¢xing in 10% TCA. Data represent percentage of GVBD.
MPF activity was analyzed as described in Section 2.
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cAMP, the activator of PKA. IBMX is an inhibitor of cAMP
phosphodiesterase which maintains high levels of cAMP,
blocking the meiotic maturation of hormones and ras [36].
IBMX also inhibited MAPK phosphorylation and GVBD in-
duced by wortmannin, supporting the results shown before.
Moreover, as expected from these results, wortmannin was
unable to activate MPF in extracts of unstimulated oocytes
(data not shown). Thus, activation of the MPF-MAPK path-
way by wortmannin most likely will induce a number of sig-
nals ending in the induction of GVBD.
Activation of the MPF-MAPK pathway is not a direct
consequence of the inhibition of the PI3K activity. Concen-
trations of wortmannin where PI3K is fully inhibited induce
entry of just a small percentage of oocytes into GVBD. More-
over, it has been reported that the microinjection of the SH2
region of the p85 regulatory subunit that also blocks PI3K
activity in Xenopus oocytes did not induce maturation by itself
[43,44]. A more likely explanation is that wortmannin is acting
through another target molecule, sustained inhibition/activa-
tion of which induces the MPF/MAPK pathway. This new
wortmannin target will be placed before protein synthesis.
In summary, wortmannin induces meiotic maturation of
Xenopus oocytes through a mechanism that is independent
of PI3 kinase inhibition but through the activation of a path-
way involving MPF and MAPK. Thus, this pathway directly
or indirectly a¡ects other proteins, besides PI3 kinase, in-
volved in cell signalling. Wortmannin-dependent activation
of this pathway is placed upstream of protein synthesis. In-
hibition of protein synthesis, MPF activation or a decrease of
cAMP levels are all able to block wortmannin-induced matu-
ration. Thus, wortmannin may be a valuable tool for the
study of the pathway leading to mitotic maturation of oo-
cytes, but it cannot be used as a speci¢c PI3 kinase inhibitor.
The identi¢cation of the novel targets for wortmannin action
may be of great interest for a better understanding of signal
transduction pathways in eukaryotic cells.
References
[1] Jacobs, T. (1992) Dev. Biol. 153, 1^15.
[2] Maller, J.L. (1998) in: Microinjection. A laboratory companion
(Lacal, J.C., Perona, R. and Feramisco, J., Eds.), Chapman and
Hall, Weinheim (in press).
[3] Minsull, J. (1993) BioEssays 15, 149^155.
[4] Gebauer, F. and Richter, J.D. (1997) BioEssays 19, 23^28.
[5] Gotoh, Y., Moriyama, K., Matsuda, S., Okumura, E., Kishimo-
to, T., Kawasaki, H., Suzuki, K., Yahara, I., Sakai, H. and
Nishida, E. (1991) EMBO J. 10, 2661^2668.
[6] Dunpny, W.G. and Newport, J.W. (1989) Cell 58, 181^191.
[7] Sagata, N., Oskarsson, M., Copeland, T., Brumbaugh, J. and
Vande Woude, G.F. (1988) Nature 335, 519^525.
[8] Minsull, J., Murray, A., Colman, A. and Hunt, T. (1991) J. Cell
Biol. 114, 767^772.
[9] Murray, A.W., Solomon, M.J. and Kirschner, M. (1989) Nature
339, 280^286.
[10] Yew, N., Mellini, M.L. and Vande Woude, G.F. (1992) Nature
355, 649^652.
[11] Nebreda, A.R., Gannon, J.V. and Hunt, T. (1995) EMBO J. 14,
5597^5607.
[12] Nebreda, A.R. and Hunt, T. (1993) EMBO J. 12, 1979^1986.
[13] Shibuya, E.K. and Ruderman, J.V. (1993) Mol. Biol. Cell 4, 781^
790.
[14] Kosako, H., Gotoh, Y. and Nishida, E. (1994) EMBO J. 13,
2131^2138.
[15] Gotoh, Y., Masuyama, N., Dell, K., Shirakabe, K. and Nishida,
E. (1995) J. Biol. Chem. 270, 25898^25904.
[16] Haccard, O., Lewellyn, A., Hartley, R.S., Erikson, E. and Maller,
J.L. (1995) Dev. Biol. 168, 677^682.
[17] Ferrell, J.E., Wu, M., Gerhart, J.C. and Martin, G.S. (1991) Mol.
Cell. Biol. 11, 1965^1971.
[18] Gotoh, Y. and Nishida, E. (1995) Mol. Reprod. Dev. 42, 486^
492.
[19] Sagata, N. (1997) BioEssays 19, 13^21.
[20] Arcaro, A. and Wymann, P. (1993) Biochem. J. 296, 297^301.
[21] Powis, G., Bonjouklian, R., Berggren, M.M., Gallegos, A., Abra-
ham, R., Ashendel, C., Zalkow, L., Matter, W.F., Dodge, J. and
Grindey, G. et al. (1994) Cancer Res. 54, 2419^2423.
[22] Thelen, M., Wymann, M.P. and Langen, H. (1994) Proc. Natl.
Acad. Sci. USA 91, 4960^4964.
[23] Chung, J., Grammer, T.C., Lemon, K.P., Kazlauskas, A. and
Blenis, J. (1994) Nature 370, 71^75.
[24] Clarke, J.F., Young, P.W., Yonezawa, K., Kasuga, M. and Hol-
man, G.D. (1994) Biochem. J. 300, 631^635.
[25] Kimura, K., Hattori, S., Kabuyama, Y., Shizawa, Y., Takaya-
nagi, J., Nakamura, S., Toki, S., Matsuda, Y., Onodera, K. and
Fukui, Y. (1994) J. Biol. Chem. 269, 18961^18967.
[26] Okada, T., Sakuma, L., Fukui, Y., Hazeki, O. and Ui, M. (1994)
J. Biol. Chem. 269, 3563^3567.
[27] Stephens, L., Smrcka, A., Cooke, F.T., Jackson, T.R., Stern-
weiss, P.C. and Hawkins, P.T. (1994) Cell 77, 83^93.
[28] Liu, X.J., Sorisky, A., Zhu, L. and Pawson, T. (1995) Mol. Cell.
Biol. 15, 3563^3570.
[29] Balla, T., Downing, G.J., Ja¡e, H., Kim, S., Zolyomi, A. and
Catt, K.J. (1997) J. Biol. Chem. 272, 18358^18366.
[30] Sue-A-Quan, A.K., Fialkow, L., Vlahos, C.J., Schelm, J.A.,
Grinstein, S., Butler, J. and Downey, G.P. (1997) J. Cell. Physiol.
172, 94^108.
[31] Gould, G.W., Jess, T.J., Andrews, G.C., Herbst, J.J., Plevin, R.J.
and Gibbs, E.M. (1994) J. Biol. Chem. 269, 26622^26625.
[32] Thomson, F.J., Moyes, C., Scott, P.H., Plevin, R. and Gould,
G.W. (1996) Biochem. J. 316, 161^166.
[33] Carnero, A., Jimenez, B. and Lacal, J.C. (1994) J. Cell. Biochem.
55, 465^476.
[34] Posada, J. and Cooper, J.A. (1992) Science 255, 212^215.
[35] Jessus, C., Rime, H., Haccard, O., van Lint, J., Goris, J., Merle-
vede, W. and Ozon, R. (1991) Development 111, 813^820.
[36] Sadler, S.E. and Maller, J.L. (1989) J. Biol. Chem. 264, 856^861.
[37] Sadler, S.E. and Maller, J.L. (1987) J. Biol. Chem. 262, 10644^
10650.
[38] Allende, C.C., Hinrichs, M.V., Santos, E. and Allende, J.E.
(1988) FEBS Lett. 234, 426^430.
[39] Goris, J., Hermann, J., Hendrix, P., Ozon, R. and Merlevede, W.
(1989) FEBS Lett. 245, 91^94.
[40] Neant, I. and Guerrier, P. (1988) Exp. Cell Res. 176, 68^79.
[41] Rime, H., NeŁant, I., Guerrier, P. and Ozon, R. (1989) Dev. Biol.
141, 169^179.
[42] Matten, W., Daar, I.O. and Vande Woude, G.F. (1994) Mol.
Cell. Biol. 14, 4419^4426.
[43] Aroca, P., Mahadevan, D. and Santos, E. (1996) Oncogene 13,
1839^1846.
[44] Chuang, L.M., Hausdor¡, S.F., Myers Jr., M.G., White, M.F.,
Birnbaum, M.J. and Kahn, C.R. (1994) J. Biol. Chem. 269,
27645^27649.
FEBS 19767 29-1-98
A. Carnero, J.C. Lacal /FEBS Letters 422 (1998) 155^159 159
